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HIV-infected patients fail to fully recover cell-mediated immunity despite HAART. To identify regulatory factors, we studied the phenotype
and function of in vitro cytomegalovirus (CMV)-stimulated T cells from HAART recipients. CFSE-measured proliferation showed CD4+ and
CD8+ cells dividing in CMV-stimulated cultures. Compared with healthy controls, CMV-stimulated lymphocytes from HAART recipients had
lower 3H-thymidine incorporation; lower IFNγ and TNFα production; higher CD4+CD27−CD28− and CD8+CD27−CD28− frequencies; lower
CD4+CD25hi; and higher FoxP3 expression in CD8+CD25hi cells. CMV-specific proliferation correlated with higher IFNγ, TNFα and IL10 levels
and higher CD4+perforin+ and CD8+perforin+ frequencies. Decreased proliferation correlated with higher CD4+CD27−CD28− frequencies and
TGFβ1 production, which also correlated with each other. Anti-TGFβ1 neutralizing antibodies restored CMV-specific proliferation in a dose-
dependent fashion. In HIV-infected subjects, decreased proliferation correlated with higher CMV-stimulated CD8+CD25hi frequencies and their
FoxP3 expression. These data indicate that FoxP3- and TGFβ1-expressing regulatory T cells contribute to decreased immunity in HAART
recipients.
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Highly active anti-retroviral therapy (HAART) increases
CD4+ cell numbers, decreases the incidence of opportunistic
infections and death, and improves the quality of life of HIV-
infected patients (Palella et al., 1998). However, immune
reconstitution in HAART recipients is incomplete as indicated
by the fact that HAART recipients with CD4+ lymphocytes
>200 cells/μl or >15% mount lower responses to vaccines
compared with uninfected controls (Kemper et al., 2003; Levin
et al., 2001; Rodriguez-Barradas et al., 2003; Weinberg et al.,
2006). Furthermore, HIV-specific immunity is infrequently
recovered (Connick et al., 2000; Iyasere et al., 2003), and these
patients do not fully reconstitute cell-mediated immunity (CMI)
against varicella zoster or cytomegalovirus (CMV) (Keane et⁎ Corresponding author. Fax: +1 303 315 1787.
E-mail address: Adriana.Weinberg@uchsc.edu (A. Weinberg).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.04.035al., 2004; Weinberg et al., 2001, 2004). The failure to
reconstitute CMV-specific CMI may have clinical conse-
quences as illustrated by cases of recurrent CMV retinitis in
patients who achieved CD4+ ≥ 200 cells/μl on HAART but
lacked evidence of CMV-specific CMI (Johnson et al., 2001;
Komanduri et al., 2001).
In recent years, special interest has been placed on studying
regulatory mechanisms operational in HIV-infected patients.
Naturally circulating CD25+ regulatory T cells were shown to
decrease HIV- and CMV-specific CMI in HIV-infected patients
(Aandahl et al., 2004). However, not much is known about the
genesis or selection of regulatory T cells during the adaptive
immune response of these patients (Vlad et al., 2005). In vitro
CMV antigenic stimulation of peripheral blood mononuclear
cells (PBMC) should permit the study of regulatory T cells in
HIV-infected patients because (1) CMV generates a potent
antigenic stimulation in HIV-infected and healthy individuals
(Elkington et al., 2003; Sylwester et al., 2005; Wills et al.,
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CMV-specific circulating T cells (Harari et al., 2004; Villacres
et al., 2001; Waldrop et al., 1997); (3) CMV has been associated
with immunosuppression in HIV-infected patients and other
hosts (Deayton et al., 2004); (4) in contrast to HIV, CMV does
not cause T cell depletion thus eliminating an important
confounder of the study of immune regulation.
In this study of in vitro stimulation by CMV antigen, we
identified T cell populations with regulatory characteristics that
could play a role in the failure to fully reconstitute CMI in
HAART recipients.
Results
In vitro expansion of CD4+ and CD8+ T lymphocytes in
response to CMV antigenic stimulation
To determine the relative contributions of CD4+ and CD8+ T
cells to in vitro CMV-stimulated PBMC proliferation, 6-day
PBMC cultures from 18 HIV-infected and 13 uninfected
subjects were tested in parallel by 3H-thymidine incorporation
and CFSE dye dilution. Stimulation with CMVantigen, but not
with control mock-infected antigen lead to significant expan-
sions of CD4+ and CD8+ T cells obtained from HIV-infected
subjects and controls (Fig. 1). The expansion of both CD4+ and
CD8+cells was further corroborated by comparing the CD4+/
CD8+ cell ratios before and after CMV stimulation, which were
not significantly different in HIV-infected subjects (mean ± SE
ratios = 0.63 ± 0.13 vs. 0.61 ± 0.10, P = 0.42, paired T test) or
controls (mean ± SE ratios = 2.56 ± 0.70 vs. 2.96 ± 0.55, P = 1,
paired T test).
Proliferation of CMV-stimulated PBMC was lower in HIV-
infected individuals compared with controls (mean ± SE log10
cpm = 3.4 ± 0.3 vs. 4.3 ± 0.2, P = 0.03; Fig. 2A). CFSE-
measured T cell division correlated with PBMC 3H-thymidine
incorporation, both in HIV-infected and in uninfected subjects
(r2 = 0.42, P = 0.009; Fig. 2B), indicating that both assays are
measures of the same biological event.
Phenotypic and functional characterization of CMV-stimulated
T lymphocytes from HIV-infected and uninfected subjects
PBMC phenotypes previously described in association with
memory, effector and regulatory T cell functions as well as
cytokine production were examined after 6 days of CMVin vitro
stimulation, corresponding to maximum proliferation (Table 1).
Although in unstimulated PBMC, the CD4+CD27−CD28− and
CD8+CD27−CD28− fully differentiated effectors were present
in similar proportions in HIV-infected and uninfected subjects
(3.7 ± 1.1% vs. 6.6 ± 4.2%, P = 0.54 and 50.1 ± 7.3% vs.
37.9 ± 1.1%, P = 0.20, respectively), after CMV stimulation,
significantly higher proportions of CD4+CD27−CD28− and
CD8+CD27−CD28− were observed in HIV-infected individuals
compared with healthy controls (19 ± 3% vs. 9 ± 2%, P = 0.008
and 37 ± 6% vs. 17 ± 4%, P = 0.01, respectively). The skewing
towards terminally differentiated effector phenotypes of CD4+
cells from HIV-infected subjects was even more evident whenwe considered that CD4+ cell percentages in CMV-stimulated
PBMC cultures from HIV-infected individuals were significant-
ly lower than in uninfected controls.
CD4+ lymphocytes bearing a high density of CD25 receptors
(CD25hi), previously associated with regulatory function (Cosmi
et al., 2003; Jonuleit and Schmitt, 2003), were present in
significantly lower frequencies in HIV-infected subjects compared
with controls (14 ± 4% vs. 35 ± 9%, P = 0.02). Prior to
stimulation, the CD4+CD25+ percentages were not significantly
different in HIV-infected and uninfected subjects (0.6 ± 0.2% vs.
0.5 ± 0.1%, P = 0.44) and the CD4+CD25hi were barely detectable
in HIV-infected and uninfected subjects (0.005 ± 0.005% and
0.003 ± 0.003%, respectively). Another cell population bearing
markers previously associated with regulatory function, the
CD8+CD25+CFSEhi (Vlad et al., 2005), tended to be overrepre-
sented in CMV-stimulated PBMC from HIV-infected vs.
uninfected subjects (9.3 ± 3.2% vs. 3.2 ± 1.2%, P = 0.10). Prior
to stimulation, there were no appreciable differences in
CD8+CD25+ frequencies in PBMC from HIV-infected and
uninfected subjects (0.2 ± 0.2% vs. 0.1 ± 0.1%, P = 0.20).
There were no significant differences between HIV-infected
individuals and healthy controls with respect to frequencies of
CD8+CD25hi; CD4+CD25+CFSEhi; CD4+CD27+CD45RO+,
CD4+CD27+CD28−, CD8+CD27+CD45RO+ and CD8+
CD27+CD28− memory lymphocytes; CD4+CD38+HLADR+
and CD8+CD38+HLADR+ activated cells; CD4+CD95+CD25−
and CD8+CD95+CD25− lymphocytes sensitized to apopto-
sis; and CD4+granzyme B+, CD8+granzyme B+, total
CD4+ perforin+ and CD8+perforin+ effectors. However, the
percentage of CD8+CD27−CD28− perforin+ effectors tended to
be lower in HIV-infected individuals compared with controls.
To identify the functional characteristics of the CMV-
selected lymphocytes, we sought correlations with cytokine
production. We measured extracellular concentrations of the
Th1 cytokines IFNγ and TNFα, which have been associated
with protective antiviral immune responses, and of the Th2
cytokines IL10 and TGFβ1, which have been associated with
regulatory T cell responses and immunosuppression for
correlation analyses. Table 2 shows that IFNγ and TNFα
concentrations tended to be lower in PBMC culture super-
natants of HIV-infected subjects compared with controls
(P = 0.06 for both IFNγ and TNFα), whereas no differences
were observed in IL10 and TGFβ1 secretion.
Correlation analyses of the phenotypes over- or underrepre-
sented among CMV-stimulated T cells of HIV-infected subjects
with cytokine production showed higher frequency of CD4+
CD28−CD27− T cells with increased production of TGFβ1
(r2 = 0.72, P = 0.0001; Fig. 3). There was a positive association
between CD4+CD25hi and IFNγ production in the PBMC
cultures of healthy individuals only (r2 = 0.94, P = 0.004). No
significant associations were found between the frequency of
CD8+CD25hi or CD8+CD27−CD28− cells and production of
any of the cytokines measured in this study. Other significant
correlations included the positive association of CD4+perforin+
effectors with IFNγ, TNFα, and IL10 levels (P of 0.01, 0.02,
and 0.04, respectively) and of CD8+perforin+ effectors with
IFNγ and IL10 levels (P of 0.05 and 0.009, respectively).
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HIV-infected and uninfected subjects
To determine the effect of in vitro CMV stimulation on the
expansion or selection of FoxP3-expressing regulatory T cells,
resting PBMC from 6 HIV-infected and 4 uninfected subjects
were sorted into CD4+ and CD8+ populations, after which FoxP3
and GAPDH mRNA were measured in each sorted population.
Cells were also labeled with CFSE and, after 6 days of in vitro
CMV stimulation, were sorted into the following groups: CD4+
CD25+CFSEhi, CD4+CD25hiCFSEhi, CD4+CD25loCFSEhi
CD8+CD25+CFSEhi, CD8+CD25hiCFSElo and CD8+CD25lo
CFSEhi (Fig. 4A). FoxP3 and GAPDH mRNA were measured
in each of the sorted cell populations. The data showed
significantly higher expression of GAPDH-normalized FoxP3 in
CMV-stimulated CD25hiCFSElo compared with CD25+CFSEhi
and CD25loCFSElo (mean ± SE = 58 ± 22 vs. 1.8 ± 1.5 and
17.3 ± 5.8 pg FoxP3/ng GAPDH, P = 0.03, Fig. 4B). The only
significant difference in FoxP3 expression of PBMC from HIV-Fig. 1. CD4+ and CD8+ cell expansions in cultures stimulated with inactivated CMV
HIV-infected (right 2 columns) and uninfected (left 2 columns) subjects. PBMC are la
verified after individually gating on each cell population (upper row). CFSE content i
mock-infected control antigen (middle row). The plots show very few dividing cells (C
of CD4+ and CD8+ cell divisions in CMV-stimulated PBMC.infected compared with uninfected subjects was observed in the
CMV-stimulated CD8+CD25hiCFSElo cells (mean ± SE = 77 ± 23
vs. 9 ± 7 pg FoxP3/ng GAPDH, P = 0.04, Fig. 4C).
Factors associated with decreased CMV-stimulated PBMC
proliferation in HIV-infected and uninfected subjects
To gain insight into the regulatory mechanisms that might
contribute to the decreased CMV-specific CMI in HAART
recipients, we identified the negative correlations of PBMC
proliferation with frequencies of specific T cell phenotypes
and cytokine production. CMV-specific proliferation de-
creased with higher frequencies of CD4+CD27−CD28−, but
not of CD8+CD27−CD28− cells, in HIV-infected and
uninfected subjects (r2 = 0.52 P = 0.002; Fig. 5A).
Proliferation also decreased with TGFβ1 production
(r2 = 0.38, P = 0.03, Fig. 5B). In addition, in vitro
treatment with neutralizing anti-TGFβ1 mAbs increased
proliferation in a dose-dependent fashion (P = 0.01, Fig. 5C).antigen. The plots represent typical examples of CFSE-measured proliferation in
beled with CFSE prior to in vitro culture, and uptake of CD4+ and CD8+ cells is
s measured again after 6 days of in vitro stimulation with CMV (bottom row) and
FSElo) in mock-infected control-stimulated cultures, but a significant proportion
Fig. 2. CMV-stimulated CD4+ and CD8+ cell proliferation in HIV-infected and
uninfected subjects. Data were derived from PBMC obtained from 18 HIV-
infected subjects on HAART and 13 uninfected controls after 6-day in vitro
culture in the presence of CMV and control antigens. PBMC proliferation
measured by 3H-Thy incorporation showed significantly lower responses among
HIV-infected subjects on HAART compared with uninfected controls (panel A).
PBMC proliferation measured by 3H-Thy incorporation was significantly
associated with CD3+ cell expansion measured by CFSE dilution (panel B) both
in 8 HIV-infected subjects (■) and 7 uninfected controls (▵).
Table 1
CMV-selected T cell phenotypes in HIV-infected and uninfected subjects
Cell population HIV infected Uninfected P value
CD4+ 25 ± 5 (19) ⁎ 53 ± 5 (18) 0.004
CD27+CD45RO+ 51 ± 16 (8) 87 ± 18 (8) 0.88
CD27+CD28− 38 ± 7 (14) 51 ± 12 (9) 0.33
CD27−CD28− 19 ± 3 (14) 9 ± 2 (9) 0.008
CD38+HLADR+ 47 ± 8 (8) 45 ± 18 (8) 0.93
CD95+CD25− 17 ± 7 (8) 10 ± 4 (8) 0.37
CD25hi 18 ± 8 (19) 35 ± 9 (18) 0.02
CD25+CFSEhi 18 ± 5 (13) 7 ± 3 (8) 0.25
Perforin+ 17 ± 9 (8) 19 ± 5 (6) 0.90
Granzyme B+ 29 ± 9 (8) 45 ± 8 (6) 0.25
CD27−CD28− perforin+ 23 ± 8 (8) 28 ± 5 (6) 0.65
CD8+ 43 ± 1 (19) 38 ± 6 (18) 0.59
CD27+CD45RO+ 44 ± 9 (8) 38 ± 19 (8) 0.88
CD27+CD28− 32 ± 9 (14) 89 ± 16 (9) 0.33
CD27−CD28− 37 ± 6 (18) 17 ± 4 (9) 0.01
CD38+HLADR+ 33 ± 8 (8) 40 ± 22 (8) 0.93
CD95+CD25− 13 ± 7 (8) 2 ± 1 (8) 0.16
CD25hi 7 ± 2 (19) 12 ± 4 (18) 0.19
CD25+CFSEhi 6 ± 2 (13) 2 ± 1 (8) 0.09
Perforin+ 12 ± 4 (8) 13 ± 5 (6) 0.82
Granzyme B+ 48 ± 9 (8) 62 ± 5 (6) 0.24
CD27−CD28− perforin+ 17 ± 8 (8) 35 ± 9 (6) 0.10
Parentheses indicate number of subjects in each experiment.
HIV-infected subjects who contributed PBMC for these experiments had median
CD4 = 322 cells/μl and plasma HIV = 435 RNA copies/milliliter.
Bold-faced rows indicate significant differences and trends.
⁎ Numbers represent mean ± S.E%.
Table 2
CMV-stimulated cytokine production of PBMC from HIV-infected individuals
and controls
Cytokine HIV infected (N = 10) Controls (N = 6) P value
IFNγ 2227 ± 982 27468 ± 18307 0.06
TNFα 528 ± 102 1220 ± 406 0.06
TGFβ1 235 ± 113 62 ± 23 0.26
IL10 85 ± 18 58 ± 13 0.63
Numbers represent cytokine concentrations measured in 6-day ex vivo
stimulated PBMC culture supernatants expressed as mean ± SE pg/ml.
HIV-infected subjects who contributed PBMC for these experiments had median
CD4 = 312 cells/μl and plasma HIV <400 RNA copies per milliliter.
Bold-faced rows indicate strong trends.
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frequencies of CMV-stimulated CD8+CD25hi cells in HIV-
infected subjects (r2 = 0.43, P = 0.01, Fig. 6A), but not in
uninfected controls (r2 = 0.05, P = 0.31). CMV-specific
proliferation of PBMC from HIV-infected individuals decreased
with enhanced expression of FoxP3 of CMV-stimulated CD8+-
CD25hi cells (r2 = 0.67, P = 0.05, Fig. 6B). These data
suggested that the CMV-stimulated CD8+CD25hi contained an
important proportion of regulatory T cells in HIV-infected
individuals.
Factors associated with increased CMV-stimulated PBMC
proliferation in HIV-infected and uninfected subjects
Robust proliferation was associated with higher IFNγ and
TNFα production (P = 0.003 and 0.006, respectively, Fig. 7).
Proliferation also increased with higher IL10 production in
HIV-infected subjects (r2 = 0.65 P = 0.05) but not in
uninfected controls. In addition, the frequency of CD4+
perforin+, CD8+perforin+, CD4+CD27−CD28− perforin+ and
CD8+CD27−CD28− perforin+ T lymphocytes increased with
higher proliferation (P = 0.03, 0.002, 0.02 and 0.01,respectively, Fig. 7). In healthy individuals, there was a
trend associating the frequency of CMV-stimulated CD4+
CD25hi lymphocytes with CMV-stimulated PBMC prolifer-
ation (r2 = 0.15, P = 0.08).
Discussion
This study identified CD4+CD27−CD28− cells expanded
by in vitro CMV stimulation as a phenotypic marker
associated with impaired proliferation suggesting that this T
cell population might contain regulatory cells. Higher CD4+-
CD27−CD28− cell frequencies were associated with de-
creased CMV-stimulated PBMC proliferation and with
higher production of TGFβ1, one of the hallmarks of
CD4+CD25− mediated regulatory activity (Fantini et al.,
2004; Jonuleit and Schmitt, 2003). CMV-specific proliferation
Fig. 3. TGFβ1 secretion correlates with the frequency of CD4+CD27−CD28−
lymphocytes in CMV-stimulated PBMC. Data were generated using PBMC
from 9 HIV-infected subjects on HAART (■) and 6 uninfected controls (▵).
TGFβ1 was measured in PBMC culture supernatant by ELISA.
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addition of anti-TGFβ1 neutralizing mAbs to CMV-stimulat-
ed PBMC cultures restored proliferation, providing direct
evidence of the regulatory role of TGFβ1 in this system.
Although higher TGFβ1 production and CD4+CD27−CD28−
percentages were associated with decreased CMV-stimulated
proliferation of PBMC obtained from both HIV-infected and
uninfected subjects, the frequency of CMV-stimulated CD4+
CD27−CD28− cells was significantly higher in PBMC from
HIV-infected compared with uninfected subjects, suggesting
that these cells might play a role in the persistence of CMV
CMI impairment in HAART recipients. The association
between the frequency of CD4+CD27−CD28− cells and
TGFβ1 secretion could be interpreted as an indication that
TGFβ1 is secreted by the CD4+CD27−CD28− cells; that
TGFβ1 stimulates the generation of CD4+CD27−CD28− cells
(Rao et al., 2005); or that it represents an indirect association.
Studies to further characterize the relationship between CD4+-
CD27−CD28− cells and TGFβ1 production are warranted.
Another group of cells that appeared to have a regulatory
effect on CMV CMI of HIV-infected subjects were the CMV-
stimulated CD8+CD25hi lymphocytes. High frequencies of
CMV-stimulated CD8+CD25hi cells correlated with decreased
PBMC proliferation from HIV-infected subjects. In addition,
the CD8+CD25hi cells isolated from CMV-stimulated PBMC
from HIV-infected subjects expressed high levels of FoxP3, a
hallmark of regulatory activity. Indeed, FoxP3 expression of
CMV-stimulated CD8+CD25hi cells negatively correlated with
PBMC proliferation. There is less published information on
CD8+ compared with CD4+ regulatory T cells. However, given
the predominance of CD8+ cells in HIV-infected individuals, it
is conceivable that these cells might assume a central regulatory
role in this patient population.
The frequencies of CD4+CD27−CD28− and CD8+CD25hi
lymphocytes were significantly higher in CMV-stimulated
compared with unstimulated PBMC from HIV-infected and
uninfected subjects indicating that these cells expanded in
response to CMV antigenic stimulation. In addition, there wereno significant associations between the frequency of
CD8+CD25+ cells in unstimulated PBMC and CMV-specific
proliferation (data not shown). Finding maximum Fox P3
expression in CMV-stimulated CFSElo T cells further supported
the notion that regulatory T cells were generated during the
antigenic stimulation process. Although in unstimulated PBMC
frequencies of CD4+CD27−CD28− or CD8+CD25hi did not
differ according to the HIV status, after CMV stimulation, the
following significant differences were noted in HIV-infected
compared with uninfected subjects: (1) CD4+CD27−CD28−
percentages in CMV-stimulated PBMC were significantly
higher in HIV-infected subjects; (2) CD8+CD25hi cells
expressed excess Fox P3 in HIV-infected subjects; and (3)
CD8+CD25hi showed regulatory features only in HIV-infected
subjects. These observations suggest that chronic HIV infection
contributes to the expansion of regulatory T cells in response to
CMV antigenic stimulation. We have previously shown that
CMV-stimulated proliferation of PBMC decreases with HIV
replication in HAART recipients. However, we did not find any
evidence of active HIV replication by ultrasensitive HIV RNA
PCR (analytical sensitivity = 20 RNA copies/ml) in 10 CMV-
stimulated PBMC cultures from HIV-infected subjects per-
formed in identical conditions compared with the experiments
reported here (Weinberg et al., 2004). It is conceivable that the
chronic HIV infection biases the immune response towards
regulation, which might be highlighted by additional antigenic
stimulation.
Naturally circulating CD4+CD25hi lymphocytes have been
previously shown to modulate HIV- and CMV-specific CMI in
HIV-infected patients (Aandahl et al., 2004; Eggena et al.,
2005; Tsunemi et al., 2005). However, we did not observe any
associations of CMV-specific proliferation with the frequen-
cies of CD4+CD25+ cells in unstimulated PBMC (data not
shown) or with those of CMV-stimulated CD4+ CD25hi cells.
To the contrary, in healthy individuals, higher frequencies of
CMV-stimulated CD4+CD25hi cells occurred in PBMC
cultures with increased CMV-induced proliferation and IFNγ
production, suggesting that the ex vivo CMV-stimulated
CD4+CD25hi T cells predominantly included Th1 effectors.
These data show that cells with similar phenotypes, i.e., CD4+
CD25hi, may have different functions depending on the
conditions in which they are generated and further underscore
the need to use multiple phenotypic markers for functional
characterization.
In our experimental model, IL10 production was not
associated with regulation. Synthesis of IL10 increased with
higher CMV-stimulated PBMC proliferation in HIV-infected
subjects. IL10 levels also increased with higher frequencies of
perforin-expressing CD4+ and CD8+ effector cells, but not with
cells expressing regulatory phenotypes. Although others
showed that IL10 production contributes to CMI down-
regulation in HIV-infected individuals (Landay et al., 1996;
Ostrowski et al., 2001, 2003), the effect of IL10 may vary with
antigen specificity or other factors.
This study confirmed previous observations that CMV-
specific CMI remains depressed in HIV-infected subjects
despite receiving HAART (Keane et al., 2004; Weinberg et
Fig. 4. FoxP3 expression in CMV-stimulated PBMC from HIV-infected subjects on HAART (N = 6) and uninfected controls (N = 4). Panel A shows the gating strategy
used for sorting different cell populations after 6 days of PBMC stimulation with CMV inactivated antigen. CD4+ or CD8+ (shown) cells were gated using surface
marker and side scatter (gate P2). Cells were then segregated according to their CFSE content and CD25 expression into CD25+CFSEhi (P3), CD25hiCFSElo (P4), and
CD25loCFSElo (P5). Panel B shows the mean FoxP3 expression in the CMV-stimulated cells. The bars represent means and SE of FoxP3 pg mRNA/GAPDH ng
mRNA (please note difference in units for FoxP3 and GAPDH) from pooled CD4+ and CD8+ cells of the indicated CD25CFSE phenotype. The data show significantly
higher expression of FoxP3 in CD25hiCFSElo pooled CD4+ and CD8+ cells (ANOVA for repeated measures). Panel C shows that CMV-stimulated CD8+CD25-
hiCFSElo (expanded) cells from HIV-infected subjects express significantly higher levels of FoxP3 compared with uninfected controls.
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HAART recipients compared with controls but also CMV-
induced Th1 cytokine production and CD8+CD27−CD28−
perforin+ effectors tended to be lower compared with healthy
controls. The frequency of perforin-expressing CD4+ and
CD8+ effector cells positively correlated with PBMC
proliferation and with the production of the Th1 cytokines
IFNγ and TNFα. These findings are in agreement with the
canonical model of antiviral cell-mediated immune responses
(Lichterfeld et al., 2004; Marchant et al., 2003; Ostrowski et
al., 2003; Rentenaar et al., 2000; Wherry and Ahmed, 2004)
and underscore the utility of these experimental conditions for
dissecting the modulatory mechanisms of these responses
including immune functions that were not addressed in this
study, such as antigen presentation.Subjects and methods
Subjects
The study was conducted using PBMC obtained from 45
HIV-infected and 15 uninfected subjects. All participants were
CMV-seropositive. Inclusion criteria for HIV-infected patients
included HAART treatment ≥3 months (three drug regimen,
including at least one protease inhibitor or a non-nucleoside
analogue) and CD4+ counts ≥100 cells/μl upon study entry.
Median CD4+ T cell count was 318 cells/μl, ranging from 130
to 735 cells/μl. HIV viral load ranged from <50 to 200,000
copies/ml, with a median of 500 copies/ml. The median time on
HAART was 20 months. HIV-infected and uninfected subjects
had similar demographic characteristics.
Fig. 5. Association of CD4+CD27−CD28− cells and of TGFβ1 secretion with
downregulation of CMV-stimulated PBMC proliferation. Panel A shows an
inverse correlation between CMV-stimulated 3H-Thy incorporation and the
frequency of CD4+CD27−CD28− cells in PBMC cultures from 10 HIV-infected
subjects on HAART (■) and 6 uninfected controls (▵). Panel B shows an
inverse correlation between CMV-stimulated 3H-Thy incorporation and the
concentration of TGFβ1 in PBMC culture supernatants from 7 HIV-infected
subjects on HAART (■) and 6 uninfected controls (▵). Panel C shows that
addition of neutralizing anti-TGFβ1 mAb in the indicated doses restores
proliferation in a dose-dependent fashion. Data were derived from 10 subjects
equally distributed between HIV-infected and uninfected groups.
Fig. 6. Association of CD8+CD25hi cell frequencies and of Fox P3 expression by
CD8+ with downregulation of CMV-stimulated proliferation of PBMC from
HIV-infected subjects on HAART. Panel A shows an inverse correlation
between CMV-stimulated 3H-Thy incorporation and the frequency of CD8+
CD25hi cells in PBMC cultures from 14 HIV-infected subjects. Panel B shows
an inverse correlation between CMV-stimulated 3H-Thy incorporation and
FoxP3 expression of CD8+CD25hi cells from HIV-infected subjects. FoxP3
levels are expressed in pg FoxP3 mRNA/ng of GAPDH mRNA.
414 R.D. Jesser et al. / Virology 352 (2006) 408–417Monoclonal antibodies and other reagents used in flow
cytometric assays
The following reagents were used in this study: carboxy-
fluorescein diacetate, succinimidyl ester (CFSE, Molecular
Probes), anti-CD4-PerCP and CD8-PerCP (Becton Dickinson),
anti-CD25-APC, anti-CD27-PE, anti-CD28-FITC, anti-CD38-FITC, anti-CD45RO-FITC, anti-CD95-FITC, anti-HLA-DR-
APC and anti-granzyme B-APC (Caltag), anti-perforin–biotin
(Ancell), and streptavidin–APC (eBiosciences). These anti-
bodies were used to identify CD4+ and CD8+ central
memory (CD45RO+CD27+), effector memory (CD7+CD28−),
activated (CD38+HLADR+), highly susceptible to apoptosis
(CD95+CD25−), cytotoxic (granzyme B+ and perforin+), and
regulatory (CD25hi) cells.
Specimen processing and cryopreservation
Peripheral blood mononuclear cells (PBMC) from hepa-
rinized blood, separated by Ficoll/Hypaque density gradient
centrifugation (Sigma Chemical Company), were cryopre-
served as previously described (Weinberg et al., 2000) at 107
cells/ml in fetal bovine serum (FBS, Gemini Bio-Products)
with 10% dimethylsulfoxide (DMSO, Sigma Chemical
Company).
Lymphocyte proliferation assay
This assay was performed as previously described
(Weinberg and Pott, 2003). PBMC at 106 cells/ml in
Fig. 7. Positive correlations of CMV-stimulated PBMC proliferation measured by 3H-Thy incorporation with IFNγ secretion in culture supernatant (panel A), TNFα
secretion (panel B), frequencies of CD4+perforin+ cells (panel C), CD8+peforin+ (panel D), CD4+CD27−CD28−perforin+ (panel E) and CD8+CD27−CD28− perforin+
(panel F). Data were derived from 7 HIV-infected (■) and 5 uninfected (▵) subjects.
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glutamine (Gibco), 10% human AB serum (GemCell) and
1% penicillin–streptomycin (Gibco) were allowed to
expand in the presence of inactivated CMV-infected cell
lysate, prepared as previously described [35], mock-
infected cell control antigen and phytohemagglutinin
(Sigma). After 6 days of culture at 37 °C in 5% CO2
atmosphere, cells were pulsed with 3H-thymidine, and
their DNA was harvested 6 h later onto unifilter plates
(Perkin Elmer). Radioactivity gathered on the filters was
counted with a microplate scintillation counter (Packard).
Results are expressed in log10 median counts per minutes
(cpm) of quadruplicate CMV-stimulated PBMC in 96-
microtiter plate wells after subtraction of the radioactivity
measured in mock-infected control antigen-stimulated
cultures.Extracellular cytokine measurements
PBMC were cultured at 106 cells/ml in stimulation medium
containing CMV- or mock-infected cell control antigens.
Culture supernatants collected after 6 days were frozen at
−70 °C until assayed with the following commercial EIA kits:
TNF-α ELISA and IFN-γ ELISA (Pierce Endogen), IL-10
ELISA (Beckman Coulter) and TGFβ1 ELISA (Biosource). All
assays were performed according to the manufacturers'
instructions. Data are expressed as differences of the cytokine
concentrations in CMV and control antigen-stimulated wells.
T cell phenotypic characterization
Unstimulated, CMV-, and mock-infected control-stimulated
T cells were studied by flow cytometry. For unstimulated
416 R.D. Jesser et al. / Virology 352 (2006) 408–417PBMC analyses, cells were processed immediately after
thawing. For stimulated cell analyses, PBMC were cultured at
106 cells/ml in RPMI 1640 with L-glutamine, 10% human AB
serum and 1% penicillin–streptomycin, in the presence of CMV
or control antigen for 6 days at 37 °C in 5% CO2 atmosphere.
Stimulated PBMC were washed in PBS and incubated with the
appropriate surface marker monoclonal antibodies for 30 min at
room temperature. For intracellular staining, PBMC were then
permeabilized and fixed (Cytofix/Cytoperm; BD Pharmingen)
for 20 min at 4 °C, washed and stained with the appropriate
reagents. After washing unbound antibodies with PBS, PBMC
were analyzed with a FACSCalibur instrument and CellQuest
software (BD Biosciences).
CFSE dilution assays and cell sorting
PBMC were labeled with 0.5 μM CFSE (Molecular Probes)
in 0.1% bovine serum albumin phosphate-buffered saline (BSA/
PBS) for 10 min at 37 °C. Staining was quenched with cold 10%
human AB serum RPMI with L-glutamine and placed on ice for
5 min. Following two washes, PBMC were resuspended in 10%
human AB serum RPMI with L-glutamine and 1% penicillin–
streptomycin at a concentration of 106 cells/ml. An aliquot of
PBMC was removed for baseline flow analysis. CMVor control
antigen was added. After 6 days of incubation at 37 °C in 5%
CO2 atmosphere, PBMC were washed in PBS and stained and
analyzed for varying surface markers as described above.
Sorting experiments were performed using a FACSAria
instrument and Diva software for analysis (BD Biosciences).
PBMC were sorted into the following populations: CD4+
CD25+CFSEh, CD8+CD25+CFSEhi, CD4+CD25hiCFSElo,
CD8+CD25hiCFSElo, CD4+CD25lo CFSElo and CD8+CD25lo
CFSElo. Sorted PBMC were collected in PBS.
Fox P3 quantitative PCR
Total RNA was extracted with RNeasy Mini Kit (Qiagen).
PBMC were washed twice in PBS, followed by treatment with
RLT buffer. For each RNA extract, the target gene, forkhead
transcription factor 3 (FoxP3) and the reference gene,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were
quantified by real-time RT-PCR using a LightCycler apparatus
(Roche). The primers and probes sequences were as follows:
FoxP3, 5′-CCACAACATGGACTACTT-3′, 5′-GCAAA-
CATGCGTGTGA-3′ and 5′-CCCTTTCACCTACGCCACG-
FL-3′, 5′-LC Red 640-CATCCGCTGGGCCATC-PH-3′;
GAPDH, 5′-TTGGTATCGTGGAAGGACTCA-3′, 5′-
TGTCATCATATTTGGCAGGTTT-3′ and 5′-TGTCCCCAC
TGCCAACGTGTCAG-FL-3′, 5′-LC Red 705-GGTGGAC
CTGACCTGCCGTCTAGA-P-3′. The one-step real-time RT-
PCR reactions were performed for each gene with One Step RT-
PCR kit (Qiagen) containing 6.25 mM magnesium chloride,
0.2 μg/μl of BSA, 0.5 μM of each primer, 0.2uM of each probe
and 3ul of RNA extract. The RT-PCR amplification consisted of
a single cycle of 30 min at 55 °C and 15 min at 95 °C, followed
by 45 cycles of 8 s at 95 °C, 12 s at 55 °C and 15 s at 72 °C. The
melting curve cycle was 10 s at 95 °C, 15 s at 45 °C and 0 s at85 °C with a temperature-transition rate of 0.2 °C/s and
continuous fluorescence acquisition. A standard curve of
100 ng, 10 ng, 1 ng and 0.1 ng human control RNA (Applied
Biosystems) was included in each run. Results were accepted if
positive and negative controls performed as expected.
Statistical analysis was performed using Instat3 (GraphPad)
and Statview 5.1 (SAS Inc.). Two-tailed parametric tests were
used for the statistical analyses after verifying that the data were
normally distributed.
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